Go Deep
Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 13,895 | 118.6 | 14.87 | 0.52 | 2,484.65 |
| Oct 2026 | 13,752 | 120.0 | 15.05 | 0.52 | 2,507.56 |
| Oct 2026 | 12,550 | 132.3 | 16.58 | 0.52 | 2,763.37 |
| Oct 2026 | 12,675 | 131.0 | 16.42 | 0.52 | 2,729.68 |
| Oct 2026 | 11,491 | 145.0 | 18.17 | 0.52 | 3,023.69 |
| Oct 2026 | 11,125 | 149.2 | 18.70 | 0.52 | 3,111.87 |
| Oct 2026 | 11,549 | 138.6 | 18.16 | 0.52 | 3,014.33 |
| Oct 2026 | 11,398 | 146.4 | 18.35 | 0.52 | 3,039.38 |
Arcutis Biotherapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 129,861,000.0 | 105,398,000.0 | 129,503,000.0 | 99,219,000.0 |
| Net Profit | 15,009,000.0 | -11,295,000.0 | 17,395,000.0 | 7,410,000.0 |
| EPS | 0.1 | -0.1 | 0.1 | 0.1 |
Arcutis Biotherapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 376,072,000.0 | 196,542,000.0 | 59,606,000.0 | 3,686,000.0 | — |
| Net Profit | -16,141,000.0 | -140,039,000.0 | -262,140,000.0 | -311,458,000.0 | — |
| EPS | -0.1 | -1.2 | -3.8 | -5.7 | — |
Arcutis Biotherapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 432,973,000.0 | 348,889,000.0 | 341,365,000.0 | 449,274,000.0 | — |
| Total Liabilities | 243,494,000.0 | 191,348,000.0 | 252,698,000.0 | 239,693,000.0 | — |
| Total Equity | 189,479,000.0 | 157,541,000.0 | 88,667,000.0 | 209,581,000.0 | — |
Owes vs Owns
Arcutis Biotherapeutics, Inc. owed $0.55 for every $1 it owned in Jun 2026, up from $0.53 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.55× | 0.56× | 0.55× | 0.74× | 0.53× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Arcutis Biotherapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 51.0%Receivables 33.8%Inventory 5.2%Fixed assets (tangible) 1.3%Intangible assets 3.4%Other assets 5.3%
How it's funded — Dec 2025
Long-term debt 24.9%Payables 2.9%Other liabilities 28.2%Shareholders' equity 43.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 221.0 | 228.0 | 271.9 | 409.6 |
| Receivables | 146.2 | 73.1 | 25.8 | 8.5 |
| Inventory | 22.6 | 14.5 | 13.1 | 7.5 |
| Fixed assets (tangible) | 5.5 | 3.0 | 3.9 | 4.6 |
| Intangible assets | 14.8 | 9.5 | 6.4 | 7.2 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 22.8 | 20.9 | 20.2 | 11.9 |
| Liabilities & equity | ||||
| Short-term debt | 1.0 | 0.8 | 0.7 | 0.7 |
| Long-term debt | 108.0 | 107.2 | 201.8 | 197.8 |
| Payables | 12.5 | 14.2 | 12.0 | 8.8 |
| Other liabilities | 122.0 | 69.1 | 38.2 | 32.4 |
| Shareholders' equity | 189.5 | 157.5 | 88.7 | 209.6 |
| Net tangible assets | 174.7 | 148.1 | 82.2 | 202.4 |
Arcutis Biotherapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -5,625,000.0 | -112,158,000.0 | -247,057,000.0 | -257,715,000.0 | — |
| Investing Activities | -30,253,000.0 | 28,820,000.0 | 180,232,000.0 | -87,199,000.0 | — |
| Financing Activities | 6,973,000.0 | 66,202,000.0 | 101,323,000.0 | 301,798,000.0 | — |